Navigating the Complexities of Alopecia: Insights from Dr. Adam Friedman
Dr. Adam Friedman's lecture at 2024 ODAC conference provided invaluable insights into the nuanced approach required when dealing with patients presenting with alopecia. Addressing the diverse array of alopecia types and their myriad presentations, Dr. Friedman emphasized the significance of a comprehensive clinical history and evaluation to formulate an effective treatment plan. By employing a cas …
Dr. Adam Friedman's lecture at 2024 ODAC conference provided invaluable insights into the nuanced approach required when dealing with patients presenting with alopecia. Addressing the diverse array of alopecia types and their myriad presentations, Dr. Friedman emphasized the significance of a comprehensive clinical history and evaluation to formulate an effective treatment plan. By employing a cas … Continue reading "Navigating the Complexities of Alopecia: Insights from Dr. Adam Friedman"
Next Steps in Derm, in partnership with Skin of Color Update, interviewed dermatologist Dr. Victoria Barbosa, associate professor at University of Chicago Medicine. Watch as Dr. Barbosa shares why it may be challenging for an alopecia patient to visit a dermatologist and why it’s important to address the psychological burden of hair loss. Hear how considering a broad differential is essential t … 
A 39-year-old woman with a history of alopecia areata presents for evaluation
of multiple macules and patches on her left mandibular face. She developed
these lesions slowly over several years, where they have remained stable for
many years. The patient’s goal now is to achieve repigmentation of the lesions.
The patient has previously used topical hydrocortisone 1% cream on the
lesions … 
Which of the following conditions is most associated with the findings in this 9-year-old boy?
A. Alopecia areata
B. Atopic dermatitis
C. Neurofibromatosis I
D. Parkinson disease
E. Tuberous sclerosis
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 